Real-World Usage of the Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons
A Two-Year Analysis from the Swedish Coronary Angiography and Angioplasty (SCAAR) Registry in Over 6,000 Patients
A Two-Year Analysis from the Swedish Coronary Angiography and Angioplasty (SCAAR) Registry in Over 6,000 Patients
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates.
Sacharias von Koch, MD, Lund University, Skåne University Hospital Lund Sweden, presented an analysis of data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) on the Prevail™ coronary paclitaxel drug-coated balloon* (DCB) from Medtronic as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
The real-world patient population analysis, which is the largest dataset of Prevail patients with nearly 1800 patients, compared the Prevail DCB to other DCBs in a complex patient population, including bifurcations, acute coronary syndrome, and diabetes.
*Prevail DCB is limited to investigational use in the U.S. and Japan.
Find More:
Cardiovascular Ambulatory Surgery Centers (ASCs) Topic Center
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
Peripheral Artery Disease Topic Center
